Delving into the Latest Updates on Immune Response Biopharma, Inc. with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1
免疫系统疾病	1

排名前五的药物类型	数量

治疗性疫苗	1
单克隆抗体	1

排名前五的靶点	数量

IL-1β(白细胞介素-1β)	1

关联

10

项与 Immune Response Biopharma, Inc. 相关的药物

Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.)

靶点-

作用机制

免疫刺激剂

在研机构

Immune Response Biopharma, Inc.

原研机构

Immune Response Biopharma, Inc.

在研适应症

类风湿关节炎

非在研适应症-

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

DiabetesVax

靶点

IL-1β

作用机制

IL-1β调节剂

在研机构

Immune Response Biopharma, Inc.

原研机构

Immune Response Biopharma, Inc.

在研适应症

糖尿病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

GP120-depleted HIV-1 vaccine(The Salk Institute for Biological Studies)

靶点-

作用机制

免疫刺激剂

在研机构-

原研机构

The Salk Institute for Biological Studies

在研适应症-

非在研适应症

获得性免疫缺陷综合征 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

5

项与 Immune Response Biopharma, Inc. 相关的临床试验

NCT02200718 / Not yet recruiting临床1期

A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety & efficacy

开始日期2020-12-31

申办/合作机构

Immune Response Biopharma, Inc.

NCT02057159 / Unknown status临床2/3期

A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo. 200 subjects with Secondary Progressive SPMS

开始日期2020-03-09

申办/合作机构

Immune Response Biopharma, Inc.

NCT02149706 / Unknown status临床2期

A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination

Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study of NeuroVax™ vs. Incomplete Freund's Adjuvant ( I F A) placebo. 150 subjects with Secondary Progressive SPMS.

开始日期2020-03-09

申办/合作机构

Immune Response Biopharma, Inc.

100 项与 Immune Response Biopharma, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Immune Response Biopharma, Inc. 相关的专利（医药）

登录后查看更多信息

13

项与 Immune Response Biopharma, Inc. 相关的文献（医药）

2008-06-28·Clinical and Experimental Immunology3区 · 医学

Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy

3区 · 医学

Article

作者: WORMSLEY, S ; JENSEN, F C ; TRAUGER, R J ; GIERMAKOWSKA, W ; CARLO, D J ; TURNER, J

SUMMARYWe have observed a treatment-associated autoproliferative response in cultured peripheral blood mononuclear cells (PBMC) of asymptomatic HIV-1-infected subjects receiving a gp120-depleted, inactivated HIV-I antigen in incomplete Freund's adjuvant (IFA; HIV-I Immunogen). The frequency and magnitude of the autoproliferative response appeared to be dose-related (P<0.05), and was not observed in subjects receiving IFA alone. Immunophenotyping of the proliferating cells demonstrated the presence of both CD4+ and CD8+ lymphocytes, with the CD4+ blasts almost exclusively expressing the CD45RO+ phenotype. A comparison of this response with the HIV-1-specific antigen stimulation responses in this cohort revealed a significant correlation between increases in HIV-1-specific cell-mediated immunity and autoproliferation (r2= 0.61, P < 0.001). These findings suggest that immunization with the HIV-1 Immunogen induces an autoproliferative response that may reflect changes in HIV-1-specific cell-mediated immunity in infected individuals.

2002-05-02·Clinical and Experimental Immunology3区 · 医学

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination

3区 · 医学

Article

作者: DIVELEY, J P ; MOSS, R B ; GIERMAKOWSKA, W K ; MORRISON, S A ; STEIGBIGEL, R T ; NARDO, C J ; WALLACE, M R ; CARLO, D J

SUMMARYWe treated a cohort of 38 HIV-infected individuals with a therapeutic vaccine (remune, HIV-1 Immunogen) in an open label study. We then determined whether baseline parameters, such as CD4 cell count, viral load and IgG levels, were predictive of the magnitude of the HIV-specific lymphocyte proliferative responses (LPRs). We demonstrate herein that there is a significant enhancement from baseline for both HIV and p24 antigen-stimulated LPRs after immunization. Using a responder definition of a stimulation index of >5 on at least two post-immunization time-points, 29/38 (76%) responded to HIV-1 antigen while 27/38 (71%) responded to native p24 antigen. Viral load and total IgG were negatively correlated, while CD4 cell counts were positively associated with the magnitude of the HIV antigen LPR. In a multivariable analysis, baseline CD4 was the best predictor of HIV antigen LPR post-immunization.

2001-10-01·HIV Clinical Trials

Long-Term Follow-Up of HIV-1–Infected Thai Patients Immunized with Remune Monotherapy

Article

作者: Sirawaraporn, W. ; Churdboonchart, V. ; Isarangkura Na Ayudthya, B. ; Rugpao, S. ; Kulpradist, S. ; Carlo, D. ; Moss, R.B. ; Sukeepaisarncharoen, W. ; Chandeying, V.

PURPOSEThe purpose of this 2-year follow-up study was to investigate the long-term effect of Remune as monotherapy for HIV-1 infection.BACKGROUNDParticipants previously enrolled in the phase II double-blind, randomized, adjuvant-controlled study of the HIV-1 Immunogen (Remune) were followed for 2 years. Open-label immunization with Remune monotherapy was given to each participant every 12 weeks. Remune, a gp 120-depleted HIV-1 that was inactivated in beta-propiolactone and irradiation, was emulsified with mineral oil (incomplete Freund's adjuvant).METHODIn Study 2101B, the effect of four doses of Remune given every 12 weeks over 40 weeks was compared to placebo in 297 asymptomatic type E HIV-infected patients [Churdboonchart et al., 2000]. A group of 17 volunteers were separated into a subset study and another 57 were excluded from analysis due to discontinuation or addition of other treatments. This 2-year follow-up study continued with open-label dosing of HIV-1 Immunogen every 12 weeks for the remaining 223 patients. Changes in CD4+ cells, CD8+ cells, and body weight were monitored at each patient visit.RESULTSOverall, immunizations were safe; common adverse events were tolerable injection site reactions. CD4+ T-cell counts remained stable over the 132-week observation period for this cohort with a slight increase of 36.01 cells/microL. CD8+ T-cell counts showed an increase from baseline during the follow-up period (415.21 cells/microL). Furthermore, we also observed an increase in body weight from baseline (1.08 kg) at week 132. In addition, baseline CD4 count appeared to predict CD4 count at week 132 (slope = 0.31, p <.0001).CONCLUSIONThese results suggest that long-term treatment of HIV-1 infection with Remune monotherapy is safe and results in a stabilization of CD4+ counts. Furthermore, it is likely that HIV-1 therapeutic immunization may show its greatest clinical benefit in participants with higher CD4+ cell counts. Such an approach may have important ramifications in developing countries where access to antiviral drugs is limited and also in early chronic HIV-1 infection when CD4+ cells are still over 300 cells/microL in order to limit the cost and toxicity.

100 项与 Immune Response Biopharma, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Immune Response Biopharma, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月19日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

1

临床3期

其他

8

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Rheumatoid arthritis vaccine(Immune Response Biopharma, Inc.)	类风湿关节炎更多	临床3期
DiabetesVax ( IL-1β )	糖尿病更多	临床前
IR-S103	-	终止
IR101E	埃博拉病毒性疾病更多	无进展
GP120-depleted HIV-1 vaccine(The Salk Institute for Biological Studies)	获得性免疫缺陷综合征更多	无进展